Starting a GLP-1 agonist like semaglutide or tirzepatide without a concurrent muscle preservation plan is like renovating a house by removing walls without reinforcing the structure first. The weight will come off, which is the point. But without deliberate attention to what is lost alongside the fat, the physical and metabolic foundation that supports long-term health outcomes is being progressively undermined at the same time. The good news is that the lean mass loss associated with GLP-1 medications is substantially preventable. The strategies required are not complicated, but they are specific, and they need to be implemented consistently throughout the treatment period, not introduced after significant lean mass loss has already occurred. Adults on the Isle of Man who are on or considering GLP-1 medications have access to the assessment, exercise, and nutrition guidance needed to do this well.
Why Standard Diet Advice Fails on GLP-1 Medications
Standard dietary advice during weight loss focuses on caloric deficit: eat less, and the body will utilise stored energy. This is correct as far as it goes, but it is inadequate as a complete strategy during GLP-1 treatment for two reasons. First, the appetite suppression produced by these medications reduces total food intake by 20 to 25 percent, creating a significant caloric deficit automatically. Attempting to add further deliberate restriction on top of this is counterproductive and increases the risk of protein and micronutrient inadequacy. Second, the body's response to caloric deficit includes increasing muscle protein catabolism to meet energy needs, and the rate of catabolism increases with the severity of the deficit. The goal during GLP-1 treatment is not to restrict calories beyond what the medication already achieves but to ensure that the calories consumed are disproportionately protein-rich and that exercise is providing the mechanical signal to protect lean tissue.
Many patients on GLP-1 agonists find that their preferences shift away from protein-dense foods during the treatment period. The delayed gastric emptying and early satiety produced by these medications mean that denser foods like meat, fish, and eggs are sometimes less well tolerated than lighter, more processed options. This creates a practical risk: the patient reduces their total calorie intake but disproportionately reduces protein, increasing lean mass loss. Identifying protein sources that are well tolerated even with reduced appetite, such as Greek yoghurt, cottage cheese, protein shakes, eggs, and soft fish, and making these the centre of each meal rather than treating them as optional additions, is the nutritional priority during GLP-1 treatment.
The Exercise Strategy: Resistance Training First
Resistance training is the primary exercise priority during GLP-1 treatment. The mechanical stimulus of loaded exercise is the most powerful available signal for muscle protein retention during a caloric deficit, and multiple studies have demonstrated that adding resistance training to caloric restriction significantly reduces lean mass loss compared with caloric restriction alone. Johanssen and colleagues published a randomised trial in Obesity in 2012 comparing aerobic exercise, resistance training, and the combination during caloric restriction, and found that resistance training was the most effective at preserving lean mass, with the combination producing the greatest total fat loss. The practical recommendation for GLP-1 users is to prioritise resistance training over aerobic exercise when both compete for limited energy and time.
The specific protocol matters. Resistance training at an intensity that challenges the muscles within 6 to 12 repetitions, performed two to three times per week targeting all major muscle groups, is supported by the evidence for lean mass preservation during weight loss. Programmes that use exclusively light weights and high repetitions, while producing cardiovascular benefits, provide an insufficient mechanical tension stimulus to maintain fast-twitch fibre mass during caloric restriction. Working with a qualified trainer to design and progressively implement a resistance programme before starting GLP-1 medication provides the best insurance against lean mass loss during the treatment period.
EMS as a Supplement for GLP-1 Users with Limited Exercise Capacity
Some patients on GLP-1 agonists, particularly in the first months of treatment, experience fatigue, nausea, or reduced energy that limits their capacity for conventional resistance training. EMS offers a practical supplement in these circumstances, providing substantial muscle activation in 20-minute sessions with lower energy demand and no external loading requirement. As established in the EMS research literature, whole-body EMS activates a high proportion of motor units across multiple muscle groups simultaneously, producing a muscle protein synthesis stimulus comparable to resistance training at considerably lower perceived exertion.
For older GLP-1 users on the Isle of Man who were not performing resistance training before starting medication and for whom joint conditions or deconditioning make beginning a full resistance programme challenging, EMS provides an accessible entry point to structured muscle stimulation. Two EMS sessions per week, combined with the protein strategy outlined above, can significantly attenuate lean mass loss during GLP-1 treatment compared with medication alone. As treatment progresses and weight reduces, improving the mechanical load tolerance of the joints and increasing energy levels may make the gradual introduction of conventional resistance training alongside EMS the logical next step.
Monitoring Progress: Measuring What Matters
Conventional weight monitoring tells you nothing about the composition of the weight being lost. A patient who loses 10 kilograms over six months on a GLP-1 agonist may have lost 7 kilograms of fat and 3 kilograms of muscle, or 9 kilograms of fat and 1 kilogram of muscle, and standard scale weight gives no information to distinguish these very different outcomes. Body composition assessment through bioelectrical impedance analysis or DEXA, performed at the start of GLP-1 treatment and every three to four months thereafter, provides the data needed to evaluate whether the muscle preservation strategy is working and to adjust it if lean mass loss is occurring at an unacceptable rate.
Grip strength measurement provides a simple, inexpensive, and clinically validated proxy for overall skeletal muscle function and can be performed at every consultation. A decline in grip strength during GLP-1 treatment is an early warning signal for accelerating lean mass loss that warrants immediate attention to the resistance training and protein components of the programme. At Zhen Wellness on the Isle of Man, clients on GLP-1 medications who are engaged in the muscle preservation programme receive body composition monitoring and grip strength assessment at regular intervals, with programme adjustments made in response to the data rather than on a fixed schedule.
- GLP-1 medications reduce food intake by 20-25% automatically; do not add further deliberate restriction on top of this
- Prioritise protein-dense foods tolerated well on GLP-1s: Greek yoghurt, cottage cheese, eggs, soft fish, protein shakes
- Target 1.6-2.0 g protein per kg of target body weight daily; this requires deliberate planning with appetite suppression
- Resistance training 2-3 times per week at 6-12 rep intensity is the primary muscle preservation exercise strategy
- EMS supplements resistance training for those with limited exercise capacity during the early treatment period
- Scale weight is meaningless without body composition data; use DEXA or BIA to monitor lean vs fat mass changes
- Grip strength is a simple proxy for muscle function; a declining grip during GLP-1 treatment warrants immediate action
Sources
- Wilding, J.P.H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.
- Johanssen, D.L., et al. (2012). Increased protein intake is associated with improved muscular outcomes after a combination of exercise modes. Obesity, 20(11), 2234-2240.
- Ida, S., et al. (2022). GLP-1 receptor agonist treatment and muscle mass change in type 2 diabetes. Diabetology International, 13(2), 532-541.
- Bauer, J., et al. (2013). Evidence-based recommendations for optimal dietary protein intake in older people. Journal of the American Medical Directors Association, 14(8), 542-559.
- Kemmler, W., et al. (2021). Whole-body electromyostimulation: a systematic review and meta-analysis. Aging Clinical and Experimental Research, 33(5), 1181-1188.